International Circulation: We all know that statins are a major part of the armamentarium for the treatment of CVD. What is your comment on the primary prevention of CVD using statins?
《国际循环》： 我们都知道，他汀是CVD治疗的一个重要部分。您对使用他汀进行CVD一级预防有何评论？
Prof. Andrew Tonkin: I think the benefits of statins as with any treatment would depend on the risk of individuals or groups of patients one is treating. Therefore patients with a known risk of CHD with a high risk of developing future events gain the greatest absolute benefit. Primary prevention in individuals in general are at a lower risk and there are ways we can identify higher risk individuals such as the presence of diabetes with known manifest CVD is one example.I think the overview of the data really does suggest that if you are treating people with sufficient high risk in primary prevention that you gain significant benefit and I think statins in general have a major role to play in primary prevention.
Andrew Tonkin教授：我认为，如同任何治疗，他汀的获益会依赖于所治疗的患者个体或群体的风险。因此，有将来发生事件高风险的已知CHD风险的患者获得最大的绝对获益。一般来说一级预防个体处于较低风险水平，我们有能够识别较高风险个体的方法，糖尿病伴已知明显CVD的存在就是一个例子。我认为数据总体的确提示，如果你在一级预防中治疗有足够高风险的个体，那么你会获得显著益处，并且我认为总体来说他汀在一级预防中扮演着重要角色。